| Autor: |
O V, Stakhina, A G, Turkina, I E, Kostina, Iu B, Kochkareva |
| Rok vydání: |
2010 |
| Předmět: |
|
| Zdroj: |
Terapevticheskii arkhiv. 82(2) |
| ISSN: |
0040-3660 |
| Popis: |
The use of imatinib mesylate (Glivec) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in whom imatinib treatment results in the development of toxic complications is small. Drug-induced interstitial pneumonitis associated with imatinib therapy is a rare complication that requires timely differential diagnosis, discontinuation of an inductor (imatinib), and altered further treatment policy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
